Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? [electronic resource]
Producer: 20130429Description: 2943-2947 p. digitalISSN:- 1569-8041
- Aged
- Aged, 80 and over
- Androgen Receptor Antagonists -- therapeutic use
- Androstenes
- Androstenols -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Disease Progression
- Docetaxel
- Drug Interactions
- Drug Resistance, Neoplasm
- Humans
- Male
- Middle Aged
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- drug therapy
- Receptors, Androgen -- metabolism
- Steroid 17-alpha-Hydroxylase -- antagonists & inhibitors
- Taxoids -- therapeutic use
- Testosterone -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.